Originally published by our sister publication Infectious Disease Special Edition
The CDC announced the release of more than 77,000 additional doses of nirsevimab-alip (Beyfortus, Sanofi/AstraZeneca), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.?
This additional supply available in 100-mg doses will be distributed immediately to physicians and hospitals through the Vaccines for Children Program and commercial channels.
The